Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Stomach Neoplasms 4Uterine Cervical Neoplasms 1Patient Compliance 1Pancreatic Neoplasms 1Head and Neck Neoplasms 1Fruquintinib 1Colorectal Neoplasms 1Carcinoma, Hepatocellular 1

Interventions

raltitrexed 1potassium oxonate 1gimeracil 1Tegafur 1S 1 (combination) 1Irinotecan 1HMPL-013 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Fruquintinib × potassium oxonate × Clear all
NCT06427005 2025-01-22

Fruquintinib Plus S-1 and Raltitrexed (RSF) for MCRC

West China Hospital

Phase 2 Unknown
66 enrolled

Fruquintinib

Data powered by HemOnc (CC BY 4.0) Colophon âš¡